Latest Posts › Global Dealmaking

Share:

Global M&A faces market headwinds in Q2

Ongoing uncertainty hampers dealmaking in second quarter of the year, but mining megadeals and the race for clean energy offer a ray of hope. Global dealmakers had a lot to contend with in the second quarter of this year....more

Global M&A loses steam but powers on

Against the odds, dealmakers put in a solid performance in 2022, but this year has seen a slow start as buyers in the US M&A market clamor for much needed regulatory clarity - Global M&A markets gave both optimists and...more

France’s M&A activity remains steadfast

French deal volume in 2022 remained at historic levels, even while deal values dipped in the final quarter of the year France’s M&A market had a solid run of deal activity in 2022 and continues to demonstrate resilience....more

Global M&A fails to impress in the third quarter

Following on from two robust first quarters, global M&A activity succumbed to prolonged market uncertainty in the third quarter. A total of 5,163 deals worth a total of US$731.3 billion changed hands during the quarter...more

Global dealmaking continues to trail 2021 in Q2

Dealmaking failed to reach the highs of the previous year as rising inflation and a challenging financing environment put some deals under question - Global dealmaking continued its bumpy return to pre-pandemic levels in...more

Global M&A markets drops to pre-pandemic levels

While global dealmaking in Q1 was down from a blockbuster 2021, there are signs deal activity could pick up later in the year - Following a record-breaking year for dealmaking, 2022 has had a relatively slow start. A total...more

European M&A reaches post-crisis high

M&A activity in Western Europe surged in Q3 on the back of strong PE interest and low UK stock prices - Dealmaking in Western Europe reached a post-crisis record in the third quarter of the year as dealmaker confidence...more

Healthcare M&A delivers promising first quarter

Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery - The global pharma, medical and biotech (PMB) sector saw US$95.4 billion in deal...more

8 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide